V8 Peptides — Engineered Performance
Research Library
AOD-9604 in Rodent Models: Obese Mice and Zucker Rats
AOD-9604Preclinical

AOD-9604 in Rodent Models: Obese Mice and Zucker Rats

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What do rodent studies report about AOD-9604? AOD-9604, the hGH 176-191 fragment with Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, was studied in three published rodent designs: 14-day infusion or intraperitoneal exposure in obese ob/ob and lean mice, beta-3 adrenergic receptor knockout mice as a mechanistic control, and a 19-day oral study in obese Zucker rats. The authors reported lower body weight or weight gain, higher lipolytic activity and no adverse effect on insulin sensitivity in the rat clamp study. These are 2000–2001 studies from one group with small designs, and they say nothing about people. Supplied for laboratory research use only.

The V8 AOD-9604 page describes the compound as a C-terminal fragment of human growth hormone (176-191) studied for lipolytic signaling without effect on IGF-1 in research models, with research areas in lipolysis, adipocyte metabolism models and fat-oxidation studies. The existing library covers its overview, its comparison with the hGH fragment and its sequence. This article does something different: it reads the rodent studies one model at a time, listing what each design was, what the authors reported and what a reader should check before relying on it. It is a laboratory-reading guide only and makes no claim about people.

The compound and what the page states

The product page gives the formula C78H123N23O23S2, the sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (176-191), a 5 mg lyophilized presentation, and ≥98% HPLC purity. The two cysteines in the sequence can form an intramolecular disulfide bond, so identity checks by mass should consider both the reduced and the oxidized form; the average mass calculated from the stated formula is about 1,815 Da. The fragment-design logic, that the lipolytic domain of growth hormone sits at the C-terminus, is discussed in the AOD-9604 explainer. The rodent literature relevant here is small, and it was produced mostly in a short period around 2000 to 2001.

Model 1: 14-day exposure in obese and lean mice

One study exposed obese (ob/ob) and lean C57BL/6J mice with human growth hormone, AOD9604 or saline for 14 days using mini-osmotic pumps and measured body weight, caloric intake, resting energy expenditure, fat oxidation, glucose oxidation, and plasma glucose, insulin and glycerol before and after exposure. It also used in vitro assays in cells transfected with the hGH receptor to ask whether AOD9604 acts through that receptor and whether it drives proliferation through it (Heffernan et al., 2001a). The title states that chronic exposure with either hGH or the modified C-terminal fragment increased fat oxidation and reduced body weight in obese mice. The abstract reads as a design report; the detailed effect sizes should be taken from the full paper.

What a laboratory should take from it is the set of readouts: the design measured substrate oxidation and energy expenditure and not only body weight, which is what distinguishes an effect on fat handling from an effect on food intake. It also included an in vitro check on the growth-hormone-receptor pathway, because the compound's rationale is that it is lipolytic without the full growth-hormone profile.

Model 2: beta-3 adrenergic receptor knockout mice

A companion study asked about mechanism. It reported that hGH and AOD9604 reduced body weight and body fat in obese mice after 14 days of chronic intraperitoneal administration, that this correlated with increased expression of beta-3 adrenergic receptor RNA, the major lipolytic receptor of fat cells, and that both agents raised the repressed beta-3 receptor RNA of obese mice to levels comparable to lean mice. In beta-3 receptor knockout mice, long-term exposure with hGH and AOD9604 failed to produce the change in body weight and the increase in lipolysis seen in wild-type controls, which the authors took as verifying the importance of the receptor. In an acute experiment, AOD9604 was also reported to increase energy expenditure (Heffernan et al., 2001b).

The knockout design is the most informative element of the set, because it tests necessity: the effect disappeared when the proposed pathway was absent. It still concerns a mouse receptor pathway, and the beta-3 receptor is far more prominent in rodent fat than in human fat, a species difference that any reader considering translation should note.

Model 3: oral exposure in obese Zucker rats

The rat study used obese Zucker rats and daily oral exposure with AOD9604 at 500 µg/kg for 19 days. It reported that the exposure reduced body weight gain by more than 50% (15.8 ± 0.6 g versus 35.6 ± 0.8 g in controls), that adipose tissue of exposed animals showed increased lipolytic activity, and that, unlike chronic exposure with intact hGH, AOD9604 showed no adverse effect on insulin sensitivity as shown by euglycemic clamp (Ng et al., 2000). The authors concluded that the lipolytic-domain analog may have potential to be developed as an orally usable and safe agent for obesity. That sentence is a statement of the authors' view in 2000 and is quoted here for context only; this article does not evaluate it, and the data are from rats.

The euglycemic clamp is a rigorous metabolic method, and its inclusion is a strength of the design. Two caveats apply: the oral route was used, so the study does not address bioavailability in the usual sense, since the abstract reports no plasma levels; and the comparator for the insulin-sensitivity claim is chronic hGH, not a no-exposure group alone.

StudySpecies and modelExposure designReported outcomeWhat to check in the full paper
Heffernan et al., 2001aObese ob/ob and lean mice14 days, mini-osmotic pumps; hGH, AOD9604, salineIncreased fat oxidation and reduced body weight in obese mice (title)Effect sizes, lean-mouse response, receptor assays
Heffernan et al., 2001bObese mice; beta-3 receptor knockout mice14 days intraperitoneal; acute energy expenditure testReduced weight and fat; effect absent in knockoutsGroup sizes, knockout background strain
Ng et al., 2000Obese Zucker rats19 days oral, 500 µg/kg dailyWeight gain reduced by over 50%; no adverse insulin-sensitivity effectClamp protocol, food intake, control for pair feeding

Reading across the three models

The three studies agree in direction: lower weight or weight gain, more lipolytic activity, no insulin-sensitivity penalty in the one study that measured it. They also share limits. All were conducted by overlapping authors in the same period. All used genetically obese rodents, ob/ob mice or Zucker rats, whose obesity arises from leptin-pathway defects, so the results speak to those backgrounds rather than to diet-induced obesity. The exposure durations are 14 to 19 days. None of the abstracts reports the pharmacokinetics of the intact peptide, a gap for the oral study in particular, since the abstract does not report how much intact peptide reached the circulation. Readers interested in that question can compare the rationale for lipidated, protease-resistant analogs in the cagrilintide pillar.

One more point on backgrounds: ob/ob mice lack leptin and obese Zucker rats carry a leptin-receptor defect, so both models are genetic obesity models, and a reader should not generalize from them to other forms of obesity without a stated reason.

Design lessons for a laboratory

Design elementPresent in the set?Why it matters
Loss-of-function armYes (beta-3 knockout)Tests whether the proposed pathway is required
Substrate oxidation and expenditureYes (mouse studies)Separates fat handling from intake
Euglycemic clampYes (rat study)Direct measure of insulin sensitivity
Intact-peptide plasma levelsNot in the abstractsNeeded to interpret route and dose
Diet-induced obesity modelNoLimits generality of the results
Independent replicationNot describedAuthors and period overlap
  • Include a necessity test. The knockout comparison is the strongest argument in the set; a pathway claim without a loss-of-function arm is weaker.
  • Measure oxidation and expenditure, not only weight. Weight alone cannot separate intake effects from fat-handling effects.
  • Pair-feed or record intake. The abstracts do not describe pair-feeding in the rat study, so food intake should be a recorded covariate.
  • State the route and justify it. Oral, pump and intraperitoneal routes differ in exposure; record the vehicle and handling, and see how to reconstitute a lyophilized peptide.
  • Verify the material. Confirm mass and purity (AOD-9604 purity testing, how to read a COA) and calculate concentrations from the formula: mass divided by molar mass divided by volume, with the calculator for the unit conversion.
  • Report sex, age and strain. See the sibling article on sex and age as design variables.

Storage on the product page is refrigeration at 2–8 °C, −20 °C for long-term, protected from heat, moisture and light. Sourcing documentation is covered in where to buy AOD-9604, with certificates in the COA library and the full catalog in the shop.

What this literature does not cover

It does not cover diet-induced obesity models, dose-response across a range, long-term safety, pharmacokinetics of the intact peptide, or independent replication. It also contains no information on use in people, and this article draws no conclusion in that direction. Where a question lies outside these studies, the honest answer is that the data are not in the abstracts read for this review.

Frequently asked questions

What is AOD-9604?

A synthetic C-terminal fragment of human growth hormone, residues 176-191, with the formula C78H123N23O23S2 on the V8 listing.

What did the 14-day mouse study measure?

Body weight, caloric intake, resting energy expenditure, fat oxidation, glucose oxidation, and plasma glucose, insulin and glycerol before and after exposure, in obese ob/ob and lean mice.

Why were beta-3 receptor knockout mice used?

To test necessity. The reported weight and lipolysis effects were seen in wild-type mice but not in knockouts, which the authors took as evidence the receptor pathway matters (Heffernan et al., 2001b).

What did the Zucker rat study report?

Daily oral AOD9604 at 500 µg/kg for 19 days reduced body weight gain by more than 50%, increased adipose lipolytic activity, and showed no adverse effect on insulin sensitivity by euglycemic clamp (Ng et al., 2000).

Does the rodent work apply to people?

These studies do not address people, and this article makes no such claim. The beta-3 receptor, for instance, is more prominent in rodent fat than in human fat.

Were plasma levels of the peptide reported?

Not in the abstracts read for this review. The pharmacokinetics of the intact peptide are a gap in the rodent record.

Are the studies independent of each other?

They share authors and a time frame, around 2000 to 2001, so agreement among them is not independent replication.

Why does the obesity model matter?

ob/ob mice and Zucker rats carry genetic defects in the leptin pathway, so results may not transfer to diet-induced obesity models.

How is AOD-9604 verified analytically?

By mass against the value calculated from the formula, about 1,815 Da, with attention to the disulfide state, and by HPLC purity.

Where are the storage conditions?

On the product page: refrigerate at 2–8 °C, −20 °C for long-term, and protect from heat, moisture and light.

Research-use statement

All material discussed here is supplied for laboratory research use only; not for human consumption, and not a drug, food or cosmetic.

Related reading: AOD-9604 Purity: Disulfide Quality and COA Checks, AOD-9604 Preclinical Literature: Study by Study, AOD-9604 Reconstitution Math and Rodent Study Parameters.

References

  1. Heffernan M, Thorburn A, Fam B, Summers R, Conway-Campbell B, Waters M, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes. 2001;25(10):1442-1449. doi:10.1038/sj.ijo.0801740
  2. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, et al. The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andβ 3-AR Knock-Out Mice. Endocrinology. 2001;142(12):5182-5189. doi:10.1210/endo.142.12.8522
  3. Ng F, Sun J, Sharma L, Libinaka R, Jiang W, Gianello R. Metabolic Studies of a Synthetic Lipolytic Domain (AOD9604) of Human Growth Hormone. Horm Res Paediatr. 2000;53(6):274-278. doi:10.1159/000053183
  4. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of Protein Pharmaceuticals: An Update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.